Trials / Terminated
TerminatedNCT02542202
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
A Pilot Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Renal Cell Carcinoma
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This pilot clinical trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with kidney cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Stereotactic Body Radiation Therapy | Undergo stereotactic body radiation therapy |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2023-03-23
- Completion
- 2023-03-23
- First posted
- 2015-09-04
- Last updated
- 2024-05-30
- Results posted
- 2024-05-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT02542202. Inclusion in this directory is not an endorsement.